Pharmacokinetics of XNW4107 in Subjects With Various Degrees of Renal Function

Phase 1

Completed

Conditions: Bacterial Infections

Interventions: Drug: XNW4107, Imipenem/Cilastatin

Registration Number: NCT04787562

Lead Sponsor: Evopoint Biosciences Inc.

Brief Summary: This is a Phase 1, open-label study to assess the PK, safety and tolerability of XNW4107, imipenem and cilastatin administered by 60-minute (60-min) IV infusion to adults with various degrees of renal insufficiency as compared to subjects with normal renal function.

Detailed Description: Not available

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 39

Inclusion Criteria

1. Adult males or females, 18 years of age or older.
2. BMI ≥ 18.5 and ≤ 39.9 (kg/m²) and weight between 50.0 and 130.0 kg (inclusive).
3. Medically healthy (Cohort 1 only) or medically stable without clinically significant acute or chronic illness (Cohorts 2-5) that may impact the assessment of PK and safety.
4. Normal renal function with eGFR ≥90 mL/min/1.73m² (Cohort 1), or renal insufficiency with eGFR 60 to <90 mL/min/1.73m² (Cohort 2), 30 to <60 mL/min/1.73m² (Cohort 3), or 15 to <30 mL/min/1.73m² (Cohort 4), ESRD receiving HDs at least 3 times per week for at least 3 months at Screening (Cohort 5)
5. Participants of reproductive potential (male or female) must be willing to use contraception.
6. Ability and willingness to abstain from alcohol, caffeine, xanthine-containing beverages or food or product containing any of these from 48 hours prior to study drug administration until discharge from the clinical unit.

Exclusion Criteria

1. Any clinically significant medical history or abnormal findings upon physical examination, or clinical laboratory tests.
2. Electrocardiogram (ECG) with QTcF interval duration equal or greater than 500 msec obtained at Screening or Check-In.
3. Results for alanine aminotransferase (ALT), aspartate aminotransferase (AST) and bilirubin greater than 1.5 × the upper limit of normal (ULN) for the reference laboratory.
4. History of chronic liver disease, cirrhosis, or biliary disease.
5. History or presence of CNS disorders, seizures, or other CNS adverse reactions such as confusional states and myoclonic activity.
6. Positive testing for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at Screening.
7. Close contact with anyone who tested positive for SARS-CoV-2 infection, or presence of symptoms associated with SARS-CoV-2 infection at Screening or Check-in, or within 14 days prior to Screening.
8. Recent history (within 6 months) of known or suspected Clostridium difficile infection.
9. Positive testing for HIV Ab, HBsAg or HCV Ab.
10. Recent history of substance or alcohol abuse within the previous year, or habitual use of tobacco or nicotine products or smoking within 3 months prior to Screening.
11. Positive drug screen and alcohol testing at Screening or Check-in.
12. For subjects with normal renal function (Cohort 1), the use of any over-the-counter (OTC) medications within 7 days prior to study drug administration or use of prescription medications including nonsteroidal anti-inflammatory drugs, health supplements, and herbal remedies taken within 13 days prior to study drug administration.
13. For subjects with renal impairment (Cohorts 2-5), the use of prohibited concomitant medication with the exception of those essential for the management of renal impairment and other concomitant stable medical conditions as per the discretion of the Investigator.
14. Use of probenecid or valproic acid within 30 days prior to study drug administration.
15. Receipt of an investigational drug within 30 days or 5 half-lives prior to the first administration of study drug, whichever is longer.
16. Known history of clinically significant hypersensitivity reaction or anaphylaxis to any medication, or history of clinically significant hypersensitivity to the study drug or any related drugs or to any of the excipients, or history of food intolerance.
17. Donation of blood or plasma within 30 days prior to dosing, or loss of whole blood of more than 500 mL within 30 days prior to dosing, or receipt of a blood transfusion within 1 year of study enrollment.

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Cohort 2: Mild renal insufficiency	XNW4107, Imipenem/Cilastatin	Participants with an eGFR 60 to \<90 mL/min/1.73m2 receive a single dose of XNW4107 250mg IV co-administered with imipenem 500mg /cilastatin 500mg
Cohort 1: normal renal function	XNW4107, Imipenem/Cilastatin	Participants with an eGFR ≥ 90 mL/min/1.73m2 receive a single dose of XNW4107 250mg IV co-administered with imipenem 500mg /cilastatin 500mg
Cohort 5: End-stage renal disease (ESRD) receiving hemodialysis (HD) therapy	XNW4107, Imipenem/Cilastatin	Participants with ESRD receiving HD therapy at least 3 times a week for at least 3 months prior to Screening visit receive a single dose of XNW4107 100mg IV co-administered with imipenem 200mg /cilastatin 200mg
Cohort 3: Moderate renal insufficiency	XNW4107, Imipenem/Cilastatin	Participants with an eGFR 30 to \<60 mL/min/1.73m2 receive a single dose of XNW4107 250mg IV co-administered with imipenem 500mg /cilastatin 500mg
Cohort 4: Severe renal insufficiency	XNW4107, Imipenem/Cilastatin	Participants with an eGFR 15 to \<30 mL/min/1.73m2 receive a single dose of XNW4107 100mg IV co-administered with imipenem 200mg /cilastatin 200mg

Primary Outcome Measures

Name	Time	Method
Maximum plasma concentration (Cmax) of XNW4107, imipenem and cilastatin in subjects with various of Renal function.	From baseline to 48 hours post-dose
The terminal elimination half-life (t1/2) of XNW4107, imipenem and cilastatin in subjects with various of Renal function.	From baseline to 48 hours post-dose
Area under the curve from time zero to infinity (AUC0-∞)of XNW4107, imipenem and cilastatin in subjects with various of Renal function.	From baseline to 48 hours post-dose
Total body clearance (CL) of XNW4107, imipenem and cilastatin in subjects with various of Renal function.	From baseline to 48 hours post-dose
Time to the maximum plasma concentration (Tmax) of XNW4107, imipenem and cilastatin in subjects with various of Renal function.	From baseline to 48 hours post-dose
Apparent steady-state volume of distribution (Vss) of XNW4107, imipenem and cilastatin in subjects with various of Renal function.	From baseline to 48 hours post-dose

Secondary Outcome Measures

Name	Time	Method
Adverse event (include SAEs) will be assessed and categorized.	From baseline up to 10 days post-dose	Safety and tolerability up to the last study visit as assessed by the percentage of treatment-emergent AEs \[including serious adverse events (SAEs)\] categorized by severity, relationship to study drug, system organ class (SOC), AE preferred term (PT), along with percentage of clinically significant changes from baseline in clinical laboratory values, physical examination, vital signs, and ECG parameters.

Trial Locations

Locations (2): Division of Clinical Pharmacology (DCP), University of Miami
🇺🇸
Miami, Florida, United States
Orlando Clinical Research Center (OCRC)
🇺🇸
Orlando, Florida, United States

Pharmacokinetics of XNW4107 in Subjects With Various Degrees of Renal Function

Recruitment & Eligibility

Study & Design

Trial Locations

Instant Trial Alerts

Instant Trial Alerts